QQ客服 官方微博 反馈留言

浏览/检索结果: 共8条，第1-8条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer 期刊论文 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 卷号: 14 作者:  Yan, Min;  Yuan, Peng;  Ouyang, Quchang;  Cheng, Ying;  Han, Guohui 收藏  |  浏览/下载：24/0  |  提交时间：2022/12/23 breast cancer  chemotherapy  efficacy  lobaplatin  neoplasm metastasis  safety   Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial 期刊论文 EUROPEAN JOURNAL OF CANCER, 2019, 卷号: 112 作者:  Zhang, Qingyuan;  Xu, Binghe;  Funasaka, Setsuo;  Saito, Kenichi;  Hiraiwa, Masahide 收藏  |  浏览/下载：28/0  |  提交时间：2019/12/05 Progression-free survival  Tolerability  Locally recurrent or metastatic breast cancer  Eribulin   Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial 期刊论文 EUROPEAN JOURNAL OF CANCER, 2019, 卷号: 112 作者:  Yuan, Peng;  Hu, Xichun;  Sun, Tao;  Li, Wei;  Zhang, Qingyuan 收藏  |  浏览/下载：19/0  |  提交时间：2019/12/05 Progression-free survival  Tolerability  Locally recurrent or metastatic breast cancer  Eribulin   Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial 期刊论文 2019, 卷号: 112, 页码: 57-65 作者:  Yuan, Peng;  Hu, Xichun;  Sun, Tao;  Li, Wei;  Zhang, Qingyuan 收藏  |  浏览/下载：20/0  |  提交时间：2020/01/03 Progression-free survival  Tolerability  Locally recurrent or metastatic breast cancer  Eribulin   Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials 期刊论文 ONCOTARGETS AND THERAPY, 2016, 卷号: 9 作者:  Liu, Xiaoqun;  Liu, Xiangdong;  Qiao, Tiankui;  Chen, Wei;  Yuan, Sujuan 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/06 bevacizumab  paclitaxel  docetaxel  breast cancer  meta-analysis   Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study 期刊论文 CHINESE MEDICAL JOURNAL, 2012, 卷号: 125, 期号: 5 作者:  Xu Bing-he;  Jiang Ze-fei;  Shen Zhen-zhou;  Guan Zhong-zhen;  Chen Zheng-dong 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/19 bevacizumab  metastatic breast cancer  angiogenesis  first-line  Chinese  docetaxel   Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study 期刊论文 2012, 卷号: 125, 期号: 5, 页码: 764-769 作者:  Xu Bing-he;  Jiang Ze-fei;  Shen Zhen-zhou;  Guan Zhong-zhen;  Chen Zheng-dong 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/13 bevacizumab  metastatic breast cancer  angiogenesis  first-line  Chinese  docetaxel   Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study 期刊论文 CHINESE MEDICAL JOURNAL, 2012, 卷号: 125 - 收藏  |  浏览/下载：5/0  |  提交时间：2020/10/26 PHASE-III  GROWTH  METAANALYSIS  PLACEBO  RISK  bevacizumab  metastatic breast cancer  angiogenesis  first-line  Chinese  docetaxel